-
RongCan Biotech Raises Pre-Series A Funding for mRNA Therapeutics Development
•
China-based nucleic acid-based therapeutics developer RongCan (Shanghai) Biotech Co., Ltd has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round led by a “reputational healthcare fund.” The proceeds will be used to accelerate product research and development (R&D), team building, and clinical studies for leading pipelines.…
-
Lee’s Pharmaceutical Reports Q3 2022 Financials with 8.8% Revenue Growth
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its Q3 2022 financial report, recording HKD 1.036 billion (USD 132.4 million) in revenues, up 8.8% year-on-year (YOY). The growth was driven by strong sales of Bredinin (mizoribine), treprostinil, and interferon α2b, which offset declines in some outpatient and surgical drugs.…
-
Marinus Pharmaceuticals Collaborates with Tenacia Biotechnology for Ganaxolone
•
Pennsylvania-based pharma company Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) has entered into a collaboration and supply agreement with China-based Tenacia Biotechnology (Shanghai) Co., Ltd. Under the agreement, Tenacia will receive exclusive development and commercialization rights to certain formulations of Marinus’s ganaxolone in mainland China, Hong Kong, Macau, and Taiwan. The deal…
-
Mirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation
•
US-based Mirati Therapeutics (Nasdaq: MRTX) is reportedly suing China-based InventisBio Co., Ltd (SHA: 688382) over allegations of trade secret misappropriation. According to a security exchange notice from InventisBio, Mirati has filed a lawsuit in the Shanghai Intellectual Property Court, requesting an injunction, damages, and confirmation of ownership of certain patents.…
-
Bio-Heart Bio to Launch Clinical Study for Rapamycin Drug-Eluting Balloon in Japan
•
China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced that it will initiate a clinical study in Japan for its rapamycin drug-eluting balloon, aimed at treating in-stent restenosis. This marks a significant step in the company’s efforts to expand its presence in the Japanese market and address a…
-
Bio-Heart Bio Receives Ethical Approval for Iberis RDN System in Hainan
•
China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced receiving ethical approval from Ruijin Hospital’s Hainan branch for its Iberis multi-electrode renal radiofrequency denervation (RDN) system. The company is on the brink of applying for clinical emergence use with the Hainan Medical Products Administration and Hainan’s health commission.…
-
BeiGene’s Brukinsa Receives EC Approval for CLL Treatment
•
China-based biotech BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced receiving marketing approval from the European Committee (EC) for a new indication of its Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib). The drug is now approved across the region to treat adult patients with treatment-naïve (TN) or relapsed/refractory…
-
Zhangjiang AI New Drug R&D Alliance Expands with New Members
•
The Zhangjiang AI New Drug R&D Alliance has welcomed new participants, including Regor Therapeutics, Roche, Hengrui Pharmaceuticals, Wuxi Biologics, LianBio, Baidu, Ainnocence, Galixir, Nutshell Therapeutics, Infinite Intelligence Pharma, and more. This expansion marks a significant step in enhancing the collaborative research efforts within the alliance. Alliance OverviewThe joint effort, initiated…
-
Subtle Medical Secures Series B Funding for AI-Powered Medical Imaging
•
Subtle Medical, an Artificial Intelligence (AI)-empowered medical imaging company based in Guangdong, has reportedly raised “tens of millions” of US dollars in a Series B financing round. The round was led by Eastern Bell Capital and Primavera Venture Partners, with contributions from Fusion Fund, 3E Bioventures, Banyan Pacific Capital, Delta…
-
Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Three New Drugs
•
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clinical trial approvals for three in-house developed drug candidates: HRS-1780, HRS-1358, and SHR-7367. These approvals mark significant milestones in the company’s pipeline development, positioning Hengrui to advance innovative treatments for chronic kidney disease and advanced malignant tumors. HRS-1780 ProfileHRS-1780 is an…
-
Rainsure Scientific Secures Series C1 Funding for Digital PCR Development
•
Rainsure Scientific, a Suzhou-based developer of digital PCR instruments and RUO detection kits, has reportedly raised “tens of millions” of renminbi in a Series C1 financing round led by Qiaodao Investment Fund. The proceeds will be used to further develop and commercialize the company’s innovative molecular diagnostics products. Company ProfileFounded…
-
CSPC Pharma’s rhTNK-tPA Accepted for Review by NMPA for Stroke Indication
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that a supplementary market filing for its recombinant human TNK tissue-type plasminogen activator for injection (rhTNK-tPA) has been accepted for review by the National Medical Products Administration (NMPA). The new indication filing is for the drug’s use as a thrombolytic therapy…
-
Asia Pacific Medical Group Secures Series A Funding for Hospital Expansion
•
Private healthcare group Asia Pacific Medical Group (APMG) has raised “hundreds of millions” of renminbi in a Series A financing round. The round was led by IDG Capital and the People’s Insurance Company of China (PICC), with participation from GL Capital. The proceeds will be used for the late phase…
-
Haisco’s HSK31858 Gains Ethical Approval for Phase II Study in NCFBE
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its drug candidate HSK31858 obtained ethical approval at the First Affiliated Hospital of Guangzhou Medical University. The in-house developed Category 1 drug will be assessed for its efficacy and safety in a multi-center, randomized, double-blind, placebo-controlled Phase II study…
-
CANbridge’s CAN106 Receives Orphan Drug Designation for Myasthenia Gravis
•
China-based rare disease firm CANbridge Pharmaceuticals Inc. (HKG: 1228) has announced receiving Orphan Drug Designation (ODD) status for its pipeline drug candidate CAN106, a long-acting monoclonal antibody (mAb) targeting C5 of the complement system, for use in myasthenia gravis (MG). Myasthenia gravis is a rare and chronic autoimmune disease caused…
-
HitGen Partners with Guangzhou AIChemEco for Automated Synthesis Technology
•
China-based HitGen Inc. (SHA: 688222) has announced a partnership with compatriot firm Guangzhou AIChemEco. The collaboration aims to advance the development and application of automated high-throughput synthesis technology, project undertaking and delivery, and the design and construction of a new compound library. Financial details of the partnership were not disclosed.…
-
Harbour BioMed Establishes Nona Biosciences for Next-Generation Antibody Development
•
Harbour BioMed (HKG: 2142), a biotech company with operations in the Netherlands, the United States, and China, has announced the establishment of a new wholly-owned subsidiary, Nona Biosciences. The new unit will provide R&D solutions to clients for next-generation antibodies and other biotherapeutic development, covering the entire spectrum from discovery…
-
Novartis Considers Sale of Non-Core Units to Fund Innovation
•
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly considering the sale of certain ‘non-core’ business units, according to unnamed insider sources cited by Bloomberg. The move aims to raise funds to support further innovation in core areas. The company is said to be evaluating its options for its respiratory…
-
Sequanta Technologies Partners with Illumina to Introduce NovaSeq X Series
•
Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, has entered into a cooperation intention agreement with Illumina (NASDAQ: ILMN) at the 5th China International Import Expo (CIIE). The deal will lead to the introduction of Illumina’s latest NovaSeq X high throughput sequencer series products. Financial details…
-
Ascletis Pharma’s PD-L1 Inhibitor ASC61 Gains NMPA IND Approval
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced the approval of the Investigational New Drug (IND) application by China National Medical Products Administration (NMPA) for its in-house developed oral programmed-death ligand 1 (PD-L1) small molecule inhibitor ASC61. This approval will accelerate the global development of the drug, which is currently…
